Compare CubeSmart (CUBE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Gilead Sciences, Inc. — how do they compare? CubeSmart trades at $37.97 (market cap $8.45B), while Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 21.6× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.65%). Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Gilead Sciences, Inc. for 111 Days on average.
| CUBE | GILD | |
|---|---|---|
Market Cap | $8.45B | $182.40B |
Volume | 2,879,532 | 4,469,821 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $155.80 |
52-Week Low | $35.36 | $116.74 |
Typical Hold Time | 89 Days | 111 Days |
Enterprise Value | $11.97B | $205.46B |
Dividend Yield | 5.65% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.51, up 0.75% with mixed technical signals showing bearish moving averages but neutral oscillators. The REIT maintains strong profitability with 29.41% net margins and has beaten earnings estimates in two of the last three quarters. Recent institutional activity shows both acquisitions and reductions in positions, while analyst consensus leans toward Hold with a $44 price target representing 17% upside potential.
CUBE presents a balanced opportunity with attractive dividend yield and improving operational trends, though elevated leverage and moderating same-store NOI growth pose risks. The stock trades at reasonable valuations relative to sector peers, with potential catalysts from supply normalization and AI-driven real estate demand. Key risks include interest rate sensitivity and competitive pressures in the self-storage sector.
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
